Drug Therapy for Rheumatoid Arthritis in Adults
Gaps in Knowledge
Applicability of the conclusions is limited, as most evidence comes from efficacy trials that exclude many typical patients with rheumatoid arthritis and are conducted in ideal settings.
The evidence about the effects of disease stage, age, concomitant therapies, and comorbidities is limited and is derived from single studies that address these potential modifiers of effectiveness and safety.
Evidence about response of subgroups defined by health status, age, coexisting conditions, comorbidities, concurrent treatments, sociodemographics, or other variables is inadequate to understand the effects of these characteristics.
The effect of timing of initiation and duration of treatment, especially whether early use of biologic disease-modifying anti-rheumatic drugs (DMARDs) is beneficial, is not well understood.
Future studies should include measurements of patient centered, quality-of-life outcomes.
Head-to-head comparisons of DMARDs and studies that focus on different combination strategies are needed.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | withdrawal | adverse events | adverse effects | certolizumab pegol | etanercept | rituximab | anakinra | infliximab
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.